group: 1.72AE0.82 vs. 1.56 (p¼0.05) and 31.82AE21.82 vs. 35.67AE16.96 (p< 0.01), respectively. At 4-months rates of TLF (2.1% vs 4.0%; p¼0.44), TVF (2.1% vs 4.0%; p¼0.44) and stent thrombosis (0.0% vs 1.0%; p¼0.33) were low and similar in Ultimaster and Xience arms respectively. The 9-month primary outcome details will be provided at presentation. Conclusions: The short term clinical outcomes in bifurcations with the new Ultimaster DES shows potential. The planned 5-year follow-up of patients will allow more clear assessment. Background: Optimal treatment of coronary bifurcations with lesions involving a major side branch (>2.75mm) is unsettled. The randomized Nordic Baltic bifurcation study IV was first to show favorable mid-term results for two-stent techniques compared to provisional side branch stenting. Two-stent techniques have been associated with more stent strut malapposition compared to main vessel only stenting. Here we present the Nordic Baltic IV OCT substudy. Methods: Patients included in the Nordic Bifurcation Study IV were offered participation in the OCT substudy before randomization. The study stent was Cypher (Cordis, US) in first half of the main study and then Xience (Abbott Vascular, US). Patients underwent OCT scan post-PCI and at 8 months follow-up. Analysis involved stent strut malapposition (primary endpoint), strut coverage and ostial side branch minimal luminal area (MLA) at 8 months follow-up. Results: A total of 31 patients were included and 27 patients had matched main vessel follow-up OCT acceptable for analysis. Cypher stent was used in 43 % vs. 31 % (p¼0.52) in the one-stent vs. two-stent group. Malapposition in the proximal main vessel after 8 months was 0.12 % vs. 1.10 % (p¼0.10), in the bifurcation segment towards the side branch 0 % vs. 0.57 % (p¼0.30) and opposite to the side branch; 1.58 % vs. 2.40 % (p¼0.72) for one-and two-stent techniques, respectively. Ostial side branch MLA was measured using QAngioOCT Cut-plane analysis (Medis Specials, NL). MLA at baseline was 2.6AE1.2 mm2 in the one-stent group, vs. 4.6AE1.5 mm2 (p¼0.002) in the two-stent group and at 8-month follow-up; 3.3AE3.0mm2 vs. 3.8AE1.5 mm2 (p¼0.64) in the one-stent, vs. two-stent group. Conclusions: In a randomized comparison of one-and two-stent techniques for treatment of bifurcation lesions with a large side branch, no significant differences in malapposition were detected. The increased ostial side branch MLA at baseline for two-stent techniques was not significantly different from one-stent techniques at 8-month follow-up. The OCT findings support the beneficial mid-term results of twostent techniques in bifurcation lesions involving a major side branch. Background: Provisional T-stenting (PTS) with regular DES is recommended strategy for coronary bifurcation treatment, however results are not optimal. POLBOS II study is continuation of POLBOS I study, in which paclitaxel-eluting stent BiOSS ExpertÒ (Balton, Poland) was assessed. Methods: In POLBOS II study patients with stable CAD or NSTE-ACS were randomized to group where dedicated bifurcation sirolimus-eluting BiOSS LIMÒ stent was implanted or to group where regular DES was used. The enrollment lasted between November 2012 and December 2013 in five centers in Poland and Spain. PTS was default strategy. An angiographic control was planned at 12 months in all patients. The primary end-point is MACE after 12 months. Here, we present complete 6-month clinical follow-up. At the time of TCT 2014 angiographic follow-up will be almost completed. Results: There were implanted 104 BiOSS LIM stents and 100 regular DES. Mean age did not differ significantly between groups (BiOSS vs DES: 66.7 vs 65.5 yrs). In BiOSS group there were significantly more patients with hypertension (97.2% vs 87.5%), diabetes (44.4% vs 37.5%) and chronic kidney disease (13.9% vs 9.5%). The
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Conclusions: Collected data demonstrate comparable immediate and short-term clinical results for both groups. Full data enable to answer the question if BiOSS LIM is comparable to regular DES and if it is superior to BiOSS Expert stent assessed in POLBOS I study.
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Natural History Of Side-Branch Jailing 5 Years After Implantation Of The Everolimus-Eluting Bioresorbable Vascular Scaffold. A 3D Optical Coherence Tomography Assessment
Thoraxcenter, Rotterdam, Netherlands
Background: The observation of tissue bridge growth after bioresorbable scaffold (BVS) implantation, together with the high strut thickness raises questions about the long-term patency of side-branches jailed by BVS. We investigated by optical coherence tomography (OCT), the fate of side-branches jailed by elective BVS implantation at a 5-years follow-up. Methods: 8/14 living patients enrolled in the Thoraxcenter cohort of ABSORB A, underwent additional OCT follow-up 5 years post BVS implantation. Side-branches jailed by BVS were identified. For assessing side-branch jailing over time, threedimensional images of side-branch ostia were obtained by dedicated rendering software. No struts were identifiable in OCT pullbacks, but neointimal bridges had developed in their place. Neointimal bridges were classified based on their relative location to the ostium as proximal, distal, proximal and distal, or crossing. Mean and minimal thickness was measured in matched frames at 2-and 5-year follow-up using QCU-CMS. Side-branch ostium area assessment was performed using dedicated software. Following three-dimensional reconstruction, a cut-plane perpendicular to the side-branch centerline was selected and side-branch ostium planimetry was performed. Results: All side branches were patent with TIMI III flow. Overall, 14 side-branches were associated with incompletely apposed struts at previous examinations. Neointimal bridges at 5 years were identified in 13 side-branches, whereas in one no bridge was visible (Table) . Minimal and mean thickness of neointimal bridges overlying side-branches were respectively reduced from 241AE92mm and 341AE106mm at 2 years to 161AE107mm and 227AE119 at 5 years (p< 0.01)
Conclusions: At long-term after BVS implantation, jailed side-branch ostia are preserved, while side-branch related struts have been replaced by thin tissue bridges. 
